246 results about "Rna expression" patented technology

The present invention is directed to novel high-throughput, low-cost, and flexible solution-based methods for RNA expression profiling, including expression of microRNAs and mRNAs.

Decreasing the expression of genes in a mammalian subject has multiple applications ranging from cancer therapy to anti-infective therapy or treatment of autosomal dominant genetic disorders. Yet, there is still a lack of efficient technologies to achieve that goal in mammalian subjects in vivo. The present invention relates to methods for decreasing gene expression by administering to a mammalian subject a recombinant adeno-associated viral vector in vivo with said vector comprising an RNA interference (RNAi) expression cassette whose RNA expression products directly or indirectly lead to a decrease in expression of the corresponding RNAi target gene. Upon successful transduction with the recombinant adeno-associated viral vector, the RNA expression products of the RNAi expression cassette will decrease the cellular concentration of the mRNA transcripts of the RNAi target gene, thus resulting in decreased concentration of the protein encoded by the RNAi target gene.

This invention relates generally to oligomers useful for modulating expression and / or activity of RNAs or genes. More particularly, the invention relates to single stranded, double stranded, partially double stranded and hairpin structured chemically modified oligomers that have a broad biodistribution profile for inhibiting RNA expression in a plurality of cells, tissues, or organs, and to methods of making and using the modified oligomers.

The present invention relates compositions and methods for microRNA expression profiling of cancer stem cells. In particular, the invention relates to a method for identifying and / or diagnosing one or more cancer stem cells, the method comprising identifying from a plurality of nucleic acid molecules, each encoding a microRNA sequence, one or more nucleic acid molecules are differentially expressed in the cancer stem cells and in one or more control cells, wherein the one or more differentially expressed nucleic acid molecules together represent a nucleic acid expression signature that is indicative for the presence of cancer stem cells. The invention further relates to a corresponding diagnostic kit of molecular markers, namely the nucleic acid expression signature. Finally, the invention is directed to a method using such nucleic acid expression signatures for preventing the proliferation and / or self-renewal of such cancer stem cells as well as to a corresponding pharmaceutical composition.

A method is described whereby dendritic cells derived from the CD34+ and CD 34−hematopoietic cell lineages are directed to become programmable antigen presenting cells. The programmed cells may be pulsed with tumor cell RNA or tumor cell RNA expression products. The protocol provides for directing the maturation of dendritic cells to become antigen presenting cells. The protocol further provides for isolating tumor cell RNA from biopsy material that has been prepared in paraffin block storage. The directed dendritic cell is provided with a plurality of tumor markers by using tumor RNA in toto, the poly A+RNA fraction or the expression product of such RNA. Once activated the dendritic cells are incubated with T4 and T8 lymphocytes to stimulate and sensitize the T lymphocytes which upon introduction either into a donor host or a nondonor recipient will provide immune response protection.

The invention concerns an integrated, qRT-PCR-based system for analyzing and reporting RNA expression profiles of biological samples. In particular, the invention concerns a fully optimized and integrated multiplex, multi-analyte method for expression profiling of RNA in biological samples, including fixed, paraffin-embedded tissue samples. The gene expression profiles obtained can be used for the clinical diagnosis, classification and prognosis of various pathological conditions, including cancer.

PCT No. PCT / US94 / 03536 Sec. 371 Date Sep. 18, 1995 Sec. 102(e) Date Sep. 18, 1995 PCT Filed Mar. 30, 1994 PCT Pub. No. WO94 / 22886 PCT Pub. Date Oct. 13, 1994Oligonucleotide-mimicking macromolecules that have improved nuclease resistance are provided. Replacement of the normal phosphorodiester inter-sugar linkages found in natural oligonucleotides with four atom linking groups provide unique compounds that are useful in regulating RNA expression and in therapeutics. Methods of synthesis and use also are disclosed.

The invention relates to an establishment method of a caffeine synthetase CRISPR / Cas9 genome editing vector. The method comprises the following steps: designing two target sequences T1 and T2 on the basis of tea tree caffeine synthetase genes; respectively establishing sgRNA expression cassettes of the target sequences T1 and T2; and carrying out enzyme digestion-coupling reaction on a double-element expression vector pYLCRISPR / Cas9P35S-H, the T1sgRNA expression cassette and the T2sgRNA expression cassette so that the T1sgRNA expression cassette and the T2sgRNA expression cassette are connected and inserted into the double-element expression vector, thereby obtaining the CRISPR / Cas9 genome editing vector. By taking the tea tree caffeine synthetase as the example, conventional PCR (polymerase chain reaction), Overlapping PCR and Golden Gate Cloning techniques are combined to establish the CRISPR / Cas9 gene editing vector comprising the tea tree caffeine synthetase double targets, thereby laying a solid foundation for application of the CRISPR / Cas9 gene editing technique in tea trees, and providing technical supports for the establishment of CRISPR / Cas9 gene editing vectors of other plants.

The present invention relates compositions and methods for microRNA (miRNA) expression profiling of colorectal cancer. In particular, the invention relates to a diagnostic kit of molecular markers for identifying one or more mammalian target cells exhibiting or having a predisposition to develop colorectal cancer, the kit comprising a plurality of nucleic acid molecules, each nucleic acid molecule encoding a miRNA sequence, wherein one or more of the plurality of nucleic acid molecules are differentially expressed in the target cells and in one or more control cells, and wherein the one or more differentially expressed nucleic acid molecules together represent a nucleic acid expression signature that is indicative for the presence of or the predisposition to develop colorectal cancer. The invention further relates to corresponding methods using such nucleic acid expression signatures for identifying one or more mammalian target cells exhibiting or having a predisposition to develop colorectal cancer as well as for preventing or treating such a condition. Finally, the invention is directed to a pharmaceutical composition for the prevention and / or treatment of colorectal cancer.

The invention provides a DNA (deoxyribonucleic acid) sequence used for circular RNA (ribonucleic acid) expression and a vector containing the DNA sequence used for circular RNA expression. The vector is inserted in a eukaryotic expression vector, a lentiviral vector, an adenovirus vector or a retroviral vector to form a series of special expression vectors for circRNA. The DNA sequence and the corresponding expression vector have the best effects, are simple and convenient to operate and are stable in results and efficient in expression (the circRNA expression level is increased by more than a hundredfold). The sequence and the corresponding vector can be widely applied to expression of various circRNA, provide a powerful research tool for the functions and mechanisms of circRNA and provide theoretical support for research and development of further determination of circRNA molecules as novel markers and disease treatment targets.

The present invention relates to recombinant RNA virus templates derived from and applicable to negative strand naturally non-segmented viruses, including the families Bornaviridae, Filoviridae, and Paramyxoviridae, and methods for generating such recombinant RNA virus templates, wherein the templates are RNA generated from two or more recombinant RNA molecules. The invention relates to the use of segmented recombinant RNA virus templates for naturally non-segmented RNA viruses to express heterologous gene products in appropriate host cell systems and / or to construct recombinant viruses taken from that family and that express, package, and / or present the heterologous gene product. The invention includes the expression products and recombinant and chimeric viruses thus prepared and vaccine and therapeutic formulations comprising the recombinant RNA viruses.

The invention relates to a newly cloned full-length sequence of a long chain non-coding RNA (Ribonucleic Acid) gene and an application method thereof. The gene can be detected in a separation sample by methods including a hybrid method or an amplification method; and the gene can be used as a tumor marker, in particular a marker of liver cancer. According to the gene sequence, a real-time quantification PCR (Polymerase Chain Reaction) primer and an in situ hybridization probe are designed and synthesized; and by detecting the expression level of the long chain non-coding RNA in a liver cancer clinical case sample, expression of the long chain non-coding RNA in liver cancer is up-regulated remarkably, and prognosis of patients with liver caner with high expression of long chain non-coding RNA is poorer. According to the gene sequence, a RNA eukaryotic expression vector in a short hairpin structure for closing the expression of the long chain non-coding RNA by RNA interference is designed and synthesized; and the expression of the long chain non-coding RN in a liver cancer cell line A is inhibited successfully by using the vector.

The present invention regards predicting a response to a therapy using RNA expression profiling. In particular, a resistance to a chemotherapy, such as tamoxifen, is predicted by comparing expressed genes in a patient on the therapy to a patient sensitive to the chemotherapy. In further embodiments, there is an RNA expression profile indicative of tamoxifen resistance in an individual. In additional embodiments, the RNA expression profile comprises DUSP6 EBP50, and / or RhoGDIa.

The present invention relates to compositions and methods for the detection and characterization of small nucleic acid molecules (e.g., RNA (e.g., small RNAs such as micro RNAs (miRNAs) and small interfering RNAs (siRNAs)) and other short nucleic acid molecules). More particularly, the present invention relates to methods for the detection and quantification of RNA expression. The present invention further provides for the detection of miRNA and siRNA variants.

A multi-gene-based assay for analysis of the following: (a) oncogene expression; (b) DNA methylation of tumor suppressor genes; (c) non-coding RNA expression (microRNA profiling); and (d) long non-coding RNA expression in cancer samples is disclosed. The assay method and device for conducting the assay are applicable to diagnosis, prognosis, and treatment of various cancers such as lung, breast, colorectal, prostate, liver, bladder; kidney, cervix, pancreatic, gastric, brain, oral, endometrium, and ovary. The assay methods allow avoidance of surgery to remove cancerous tissue.

A system and method for developing and utilizing particle-based n-multiplexed assays that include three or more reporters utilizes n particle sets that are associated with particle identification images or labels (IDs) that differ between sets. The encoded particles for a given set are coated with a specific binding member, or in the case of the sandwich assay with coupled capture and detector binding pair members, to form particle types. The sets of particle types are then pooled, and aliquots of the particle types are removed to assay vessels. Next, samples with three or four reporter molecules are supplied to the respective vessels. After one or more incubation periods, the particles are supplied to a reader system, which determines the particle IDs to identify the particle types and also detects the reporter signals. The reader system includes multiple excitation lasers that excite the various reporters in sequence or in parallel, to supply associated signals to one or more detectors. Emission filters and wavelength discriminators are included such that a given detector receives at a given time the signals associated with a single assay binding label. The system further develops greater capacity sandwich assays by assigning subsets of capture and detector antibody pairings to the three or four reporters, respectively. The system performs greater numbers of differential RNA expressions based on the use of the three or more reporters, with one or more reporters assigned to the reference sample and the other reporters assigned to respective test samples. The system and method are also capable of performing greater numbers of SNPs utilizing primer extension reactions, by assigning different color reporters to the respective nucleotides or terminators.

The present invention relates to a therapeutic method using RNAi directed at BRAF, of which the point mutation, especially V599E, occurs frequently in melanomas. RNAi specific for the mutated BRAF will provide a specific therapeutic intervention for cancers such as malignant melanoma. Several target sequences for RNAi were selected in the protein coding region of the BRAF mRNA. The short hairpin RNA expression cassette was constructed on the lentiviral vector. One recombinant viral vector for the mutated BRAF V599E and two other vectors sites for wild type BRAF were constructed to infect various malignant melanoma cell lines, and the effects on the growth inhibition and the signaling of MAPK pathway were examined. The inhibitory effect on the invasion ability of malignant melanoma cell line and in vivo growth of a malignant melanoma cell line were examined.

The present disclosure relates to compositions and methods for assessing relative macromolecule abundance (e.g., RNA expression levels) in a spatially-defined manner across a tissue sample, specifically providing deep transcriptomic coverage at high-resolution across multiple locations assessed across the tissue sample.

The invention discloses a backbone plasmid carrier for genetic engineering. In the backbone plasmid carrier, a guide RNA (Ribonucleic Acid) expression frame and a Cas9 nuclease expression frame are positioned in one same double-element carrier; the guide RNA expression frame sequentially consists of a rice U6 promoter, a spectinomycin resistance gene, an artificially synthesized sgRNA backbone sequence and a Poly-T terminator; the Cas9 nuclease expression frame sequentially consists of a ZmUBI promoter, a rice preference codon modified Cas9 coded sequence and a 35s terminator. The invention further discloses a recombinant carrier which is established by using the plasmid carrier and contains a target sequence, and an application of the recombinant carrier in rice gene targeting.

Therapeutic oligonucleotide analogues which have improved nuclease resistance and improved cellular uptake are provided. Replacement of the normal phosphorodiester inter-sugar linkages found in natural oligomers with four atom linking groups forms unique di- and poly-nucleosides and nucleotides useful in regulating RNA expression and in therapeutics. Methods of synthesis and use are also disclosed.

The present invention relates to compositions and methods for the detection and characterization of interfering RNAs such as micro RNAs (miRNAs) and small interfering RNAs (siRNAs) and other short nucleic acid molecules. More particularly, the present invention relates to improved methods for the detection and quantitation of interfering RNA expression. The present invention further provides for the detection of variants and types of miRNAs and siRNAs.

Therapeutic oligonucleotide analogues which have improved nuclease resistance and improved cellular uptake are provided. Replacement of the normal phosphorodiester inter-sugar linkages found in natural oligomers with four atom linking groups forms unique di- and poly-nucleosides and nucleotides useful in regulating RNA expression and in therapeutics. Methods of synthesis and use are also disclosed.

A platform to perform normalization and correction on gene expression datasets and combines different datasets into a standard dataset using a framework configured to continuously incorporate new gene expression data. The framework determines a series of conversion factors that are used to on-board new gene expression datasets, such as unpaired datasets, where these conversion factors are able to correct for variations in data type, variations in gene expressions, and variations in collection systems.

A method for the diagnosis, prognosis and treatment of lung cancer by detecting at least one microRNA in peripheral blood is disclosed.

The invention provides a self-processing RNA expression cassette which includes at least one pair of processing units, an RNAi effecter sequence of predetermined length that regulates target gene expression which is flanked by said pair of processing units; and at least one pair of cognate ribozyme cis-cleavage target sites located 5′ and 3′ of the RNAi effecter sequence. The self-processing RNA expression cassette is able to express in vivo and in vitro and the RNAi effecter sequence includes at least one target recognition sequence derived from the Hepatitis B Virus (HBV) X gene (HBx).

Multi-modal approaches to predict tumor immune infiltration are based on integrating gene expression data and imaging features in a neural network-based framework. This framework is configured to estimate percent composition, and thus immune infiltration score, of a patient tumor biopsy sample. Multi-modal approaches may also be used to predict cell composition beyond immune cells via integrated multi-layer neural network frameworks.

Methods and devices for delivering aerosolized formulations containing polynucleotides to specified regions within a subject's respiratory tract are disclosed. The methods find use in the delivery of ribozymes, antisense polynucleotides, and DNA and RNA expression vectors into airway epithelial cells, alveoli, pulmonary macrophages and other cells in the respiratory tract (including the oropharynx, nose, nasopharynx). These methods may be used for optimization of transfection efficiency and expression in vivo, and for in vivo expression, for example for generating an immune response, or inducing immunological tolerance.

The invention discloses a triple minRNA for resisting virus infection of aids and the construction method thereof. The sequences of the triple minRNA are respectively designed according to gene sequences of ccr5, pol and vif and combined to be miRNA oligomeric and single strand DNA, then double-strand DNA is formed through annealing, then double-strand DNA is respectively inserted into the expression vector of pcDNA<TM> 6.2-GW / EmGFPmiR of miRNA to built the mi RNA expression plasmid, and the jamming effect of mi RNA expression plasmid to target gene can be detected through a Qpcr method. A miRNA string with the best gene interference effect to ccr5, vif and pol is inserted into a carrier of pcDNA 6.2 <TM>-GW / EmGFP, so as to obtain a series-wound interference vector of pcDNA6.2<TM>-GW / EmGFP-ccr5-pol-vif, and then the miR-ccr5-pol-vif in the series-wound interference vector is transferred to a lentiviral vector pLenti6.3 / V5-DEST so as to construct pLenti6.3 / V5-DEST miR-ccr5-pol-vif. The recombinant lentiviral vector can product three miRNA at the same time to cause interference effects to gene ccr5, gene pol and gene vif, so as to prevent the gene ccr5, the gene pol and the gene vif from expressing corresponding protein. Therefore, the effect of controlling Hiv infection and replication can be achieved.